Literature DB >> 33683471

Outcome Scores in Pediatric Rheumatology.

Gabriella Giancane1,2, Silvia Rosina1, Alessandro Consolaro1,2, Nicolino Ruperto3.   

Abstract

PURPOSE OF REVIEW: Providing a summary of the latest research on outcome measures in juvenile idiopathic arthritis, childhood -onset systemic lupus erythematosus, and juvenile dermatomyositis. RECENT
FINDINGS: A rational management of patients with pediatric rheumatic diseases requires the regular assessment of the level of disease activity and damage, as well as the evaluation of therapeutic response through validated and standardized outcome measures. Ideally, such tools should be simple, feasible, and easily applicable in routine care. Recently, there has been a great deal of effort to refine existing tools and devise novel outcome measures, aiming to address the various aspects of disease impact and to improve the reliability of research studies and clinical trials. The newest outcome tools in pediatric rheumatology have markedly enlarged the spectrum of health domains assessable in a standardized way, thus increasing the reliability of evaluation of clinical response and fostering future clinical trials.

Entities:  

Keywords:  Activity assessment; Core set measures; Damage assessment; Definition of improvement; Disease state criteria; Outcome measures

Year:  2021        PMID: 33683471     DOI: 10.1007/s11926-021-00988-x

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  64 in total

Review 1.  Developing outcome measures for paediatric rheumatic diseases.

Authors:  Hermine I Brunner; Angelo Ravelli
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-10       Impact factor: 4.098

2.  Preliminary definition of improvement in juvenile arthritis.

Authors:  E H Giannini; N Ruperto; A Ravelli; D J Lovell; D T Felson; A Martini
Journal:  Arthritis Rheum       Date:  1997-07

3.  Parent and child acceptable symptom state in juvenile idiopathic arthritis.

Authors:  Giovanni Filocamo; Alessandro Consolaro; Benedetta Schiappapietra; Nicolino Ruperto; Angela Pistorio; Nicoletta Solari; Silvia Pederzoli; Sara Verazza; Alberto Martini; Angelo Ravelli
Journal:  J Rheumatol       Date:  2012-02-01       Impact factor: 4.666

4.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

Authors:  D J Lovell; E H Giannini; A Reiff; G D Cawkwell; E D Silverman; J J Nocton; L D Stein; A Gedalia; N T Ilowite; C A Wallace; J Whitmore; B K Finck
Journal:  N Engl J Med       Date:  2000-03-16       Impact factor: 91.245

5.  Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology.

Authors:  N Ruperto; A Ravelli; A Pistorio; C Malattia; S Cavuto; L Gado-West; A Tortorelli; J M Landgraf; G Singh; A Martini
Journal:  Clin Exp Rheumatol       Date:  2001 Jul-Aug       Impact factor: 4.473

6.  Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis.

Authors:  Stefania Viola; Enrico Felici; Silvia Magni-Manzoni; Angela Pistorio; Antonella Buoncompagni; Nicolino Ruperto; Federica Rossi; Manuela Bartoli; Alberto Martini; Angelo Ravelli
Journal:  Arthritis Rheum       Date:  2005-07

7.  A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.

Authors:  Nicolino Ruperto; Kevin J Murray; Valeria Gerloni; Nico Wulffraat; Sheila Knupp Feitosa de Oliveira; Fernanda Falcini; Pavla Dolezalova; Maria Alessio; Ruben Burgos-Vargas; Fabrizia Corona; Richard Vesely; Helen Foster; Joyce Davidson; Francesco Zulian; Line Asplin; Eileen Baildam; Julia Garcia Consuegra; Huri Ozdogan; Rotraud Saurenmann; Rik Joos; Angela Pistorio; Pat Woo; Alberto Martini
Journal:  Arthritis Rheum       Date:  2004-07

Review 8.  Health-related quality of life in children with rheumatic diseases.

Authors:  Hermine I Brunner; Edward H Giannini
Journal:  Curr Opin Rheumatol       Date:  2003-09       Impact factor: 5.006

Review 9.  Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress.

Authors:  Giovanni Filocamo; Alessandro Consolaro; Cristina Ferrari; Angelo Ravelli
Journal:  Clin Exp Rheumatol       Date:  2013-08-26       Impact factor: 4.473

10.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

Authors:  Nicolino Ruperto; Daniel J Lovell; Pierre Quartier; Eliana Paz; Nadina Rubio-Pérez; Clovis A Silva; Carlos Abud-Mendoza; Ruben Burgos-Vargas; Valeria Gerloni; Jose A Melo-Gomes; Claudia Saad-Magalhães; Flavio Sztajnbok; Claudia Goldenstein-Schainberg; Morton Scheinberg; Immaculada Calvo Penades; Michael Fischbach; Javier Orozco; Philip J Hashkes; Christine Hom; Lawrence Jung; Loredana Lepore; Sheila Oliveira; Carol A Wallace; Leonard H Sigal; Alan J Block; Allison Covucci; Alberto Martini; Edward H Giannini
Journal:  Lancet       Date:  2008-07-14       Impact factor: 79.321

View more
  2 in total

1.  Serine, N-acetylaspartate differentiate adolescents with juvenile idiopathic arthritis compared with healthy controls: a metabolomics cross-sectional study.

Authors:  Kimberly A Lewis; Nico Osier; Ruy Carrasco; Jennifer Chiou; Patricia Carter; Alexandra Garcia; Elena Flowers; Efstathios D Gennatas; Christina Nguyen; Ambreen Rana; Sharon A Brown; Stefano Tiziani
Journal:  Pediatr Rheumatol Online J       Date:  2022-02-10       Impact factor: 3.413

2.  No evidence that genetic predictors of susceptibility predict changes in core outcomes in JIA.

Authors:  Annie Yarwood; Stephanie Shoop-Worrall; Elena López-Isac; Samantha Louise Smith; Andrew P Morris; John David Bowes; Melissa Tordoff; Kimme L Hyrich; Wendy Thomson; Stephen Eyre
Journal:  Rheumatology (Oxford)       Date:  2022-10-06       Impact factor: 7.046

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.